Especially Temsirolimus shows promising anti-tumour activity in HNSCC cell lines with low EGFR expression [231] and also in combination with Carboplatin and Paclitaxel [232], or Bevacizumab and Cetuximab [233]. This evidence concerns the gene EGFR and neoplasm.